SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-006284
Filing Date
2023-02-28
Accepted
2023-02-28 17:00:19
Documents
12
Period of Report
2023-02-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 34139
  Complete submission text file 0001493152-23-006284.txt   207908

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE gtbp-20230223.xsd EX-101.SCH 3236
3 XBRL LABEL FILE gtbp-20230223_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE gtbp-20230223_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3591
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 23686873
SIC: 2834 Pharmaceutical Preparations